Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-06651600

First Posted Date: 2020-11-18

Last Posted Date: 2021-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT04634565

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
North District of Peking University Third Hospital, Beijing, China

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07258669
Drug: Placebo

First Posted Date: 2020-11-16

Last Posted Date: 2024-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04628793

Locations: 🇺🇸
QPS-MRA, LLC-Main Office, South Miami, Florida, United States

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Non-small-cell Lung Cancer
Urothelial Carcinoma
Colorectal Carcinoma
Ovarian Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Renal Cell Carcinoma

Interventions: Biological: PF-07209960

First Posted Date: 2020-11-16

Last Posted Date: 2024-07-29

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT04628780

Locations: 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States
🇺🇸
The University of Texas MD Anderson Cancer Center- Investigational Pharmacy, Houston, Texas, United States

and more 10 locations

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07304814

First Posted Date: 2020-11-13

Last Posted Date: 2021-01-06

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT04627532

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections

Completed

Conditions: Gram Negative Infections

Interventions: Drug: Ceftazidime-avibactam

First Posted Date: 2020-11-13

Last Posted Date: 2024-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 189

Registration Number: NCT04628572

Locations: 🇮🇳
Fortis Hospital, Bhandup West, India
🇮🇳
Metro Hospital, Noida, India
🇮🇳
Grant Medical Foundation Ruby Hall Clinic, Pune, India

and more 4 locations

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: tofacitinib

First Posted Date: 2020-11-10

Last Posted Date: 2025-04-15

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT04624230

Locations: 🇮🇹
A.O.U. Federico II, Napoli, Naples, Italy
🇮🇹
ASST Papa Giovanni XXIII Epatologia e Gastroenterologia Pediatrica e dei Trapianti, Bergamo, BG, Italy
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 76 locations

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: PF-06882961
Drug: Rosuvastatin
Drug: Midazolam

First Posted Date: 2020-11-09

Last Posted Date: 2023-12-01

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT04621227

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Active, not recruiting

Conditions: Neoplasms
Embolism

Interventions: Drug: Apixaban
Drug: Rivaroxaban
Drug: Edoxaban
Drug: Dabigatran
Drug: VKA
Drug: LMWH

First Posted Date: 2020-11-06

Last Posted Date: 2025-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT04618913

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

Phase 2

Completed

Conditions: Diabetes
Obesity

Interventions: Other: Placebo
Drug: PF-06882961

First Posted Date: 2020-11-05

Last Posted Date: 2022-12-08

Lead Sponsor: Pfizer

Target Recruit Count: 151

Registration Number: NCT04617275

Locations: 🇺🇸
Emerson Clinical Research Institute, Washington, District of Columbia, United States
🇺🇸
Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸
Solaris Clinical Research, Meridian, Idaho, United States

and more 34 locations

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Phase 1

Completed

Conditions: Overweight and/or Obesity

Interventions: Drug: PF-06882961 100 mg

First Posted Date: 2020-11-04

Last Posted Date: 2022-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT04616339

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy